Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rulonilimab combined with chemotherapy in advanced NSCLC
NCT05741021Phase 2Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rulonilimab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
rulonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05741021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741021.